PH26788A - Chloroaniline derivatives - Google Patents
Chloroaniline derivatives Download PDFInfo
- Publication number
- PH26788A PH26788A PH38346A PH38346A PH26788A PH 26788 A PH26788 A PH 26788A PH 38346 A PH38346 A PH 38346A PH 38346 A PH38346 A PH 38346A PH 26788 A PH26788 A PH 26788A
- Authority
- PH
- Philippines
- Prior art keywords
- group
- ether
- evaporated
- vacuo
- compound
- Prior art date
Links
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical class ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 115
- -1 } } thiazolyl Chemical group 0.000 claims description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 13
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
- 229960004217 benzyl alcohol Drugs 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 206010062109 Reversible airways obstruction Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000005864 Sulphur Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Chemical group 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 123
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- 239000000203 mixture Substances 0.000 description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
- 239000003921 oil Substances 0.000 description 61
- 235000019198 oils Nutrition 0.000 description 61
- 239000000243 solution Substances 0.000 description 60
- 239000000543 intermediate Substances 0.000 description 54
- 238000003818 flash chromatography Methods 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 23
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 13
- 239000000284 extract Substances 0.000 description 13
- 239000003054 catalyst Substances 0.000 description 11
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000001530 fumaric acid Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000004450 alkenylene group Chemical group 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000012279 sodium borohydride Substances 0.000 description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 125000005002 aryl methyl group Chemical group 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000004419 alkynylene group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000008570 general process Effects 0.000 description 5
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 229910003445 palladium oxide Inorganic materials 0.000 description 5
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 238000001665 trituration Methods 0.000 description 5
- ASMDVSNJKLMBNN-UHFFFAOYSA-N 1-bromo-6-hex-5-ynoxyhexane Chemical compound BrCCCCCCOCCCCC#C ASMDVSNJKLMBNN-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
- 229940029284 trichlorofluoromethane Drugs 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 2
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 2
- RDDLACAKPAHDFZ-UHFFFAOYSA-N 2-(1,3-benzoxazol-2-yl)ethanol Chemical compound C1=CC=C2OC(CCO)=NC2=C1 RDDLACAKPAHDFZ-UHFFFAOYSA-N 0.000 description 2
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- RHFFTKFRGCOLOT-UHFFFAOYSA-N 3-(1,3-thiazol-2-yl)prop-2-yn-1-ol Chemical compound OCC#CC1=NC=CS1 RHFFTKFRGCOLOT-UHFFFAOYSA-N 0.000 description 2
- WNDMVILBFVSWLJ-UHFFFAOYSA-N 3-(1,3-thiazol-2-yl)propan-1-ol Chemical compound OCCCC1=NC=CS1 WNDMVILBFVSWLJ-UHFFFAOYSA-N 0.000 description 2
- VKBZBWPMGQXAGU-UHFFFAOYSA-N 3-(1-benzylbenzimidazol-2-yl)propan-1-ol Chemical compound OCCCC1=NC2=CC=CC=C2N1CC1=CC=CC=C1 VKBZBWPMGQXAGU-UHFFFAOYSA-N 0.000 description 2
- GLXQBTWGXGPFPK-UHFFFAOYSA-N 6-pyrimidin-2-ylhexan-1-ol Chemical compound OCCCCCCC1=NC=CC=N1 GLXQBTWGXGPFPK-UHFFFAOYSA-N 0.000 description 2
- SKDRAZZKVWNQCN-UHFFFAOYSA-N 6-pyrimidin-5-ylhex-5-yn-1-ol Chemical compound OCCCCC#CC1=CN=CN=C1 SKDRAZZKVWNQCN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000005283 haloketone group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- GOQJMMHTSOQIEI-UHFFFAOYSA-N hex-5-yn-1-ol Chemical compound OCCCCC#C GOQJMMHTSOQIEI-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- NSVFAVFBJYCRAC-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O.CCN(CC)CC NSVFAVFBJYCRAC-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- ATKJJUFAWYSFID-UHFFFAOYSA-N 1-(4-amino-3,5-dichlorophenyl)-2-bromoethanone Chemical compound NC1=C(Cl)C=C(C(=O)CBr)C=C1Cl ATKJJUFAWYSFID-UHFFFAOYSA-N 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- REKVZAFNJAMAQL-UHFFFAOYSA-N 2-(2-methyl-1,3-thiazol-4-yl)ethanol Chemical compound CC1=NC(CCO)=CS1 REKVZAFNJAMAQL-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- WGFCNCNTGOFBBF-UHFFFAOYSA-N 2-bromopyrazine Chemical compound BrC1=CN=CC=N1 WGFCNCNTGOFBBF-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- QKJAZPHKNWSXDF-UHFFFAOYSA-N 2-bromoquinoline Chemical compound C1=CC=CC2=NC(Br)=CC=C21 QKJAZPHKNWSXDF-UHFFFAOYSA-N 0.000 description 1
- DQSHFKPKFISSNM-UHFFFAOYSA-N 2-methylbenzoxazole Chemical compound C1=CC=C2OC(C)=NC2=C1 DQSHFKPKFISSNM-UHFFFAOYSA-N 0.000 description 1
- BXGYBSJAZFGIPX-UHFFFAOYSA-N 2-pyridin-2-ylethanol Chemical compound OCCC1=CC=CC=N1 BXGYBSJAZFGIPX-UHFFFAOYSA-N 0.000 description 1
- VPDAGUVEZGEHJJ-UHFFFAOYSA-N 2-quinolin-2-ylethanol Chemical compound C1=CC=CC2=NC(CCO)=CC=C21 VPDAGUVEZGEHJJ-UHFFFAOYSA-N 0.000 description 1
- CQFSGSFSOWEIGO-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)propan-1-ol Chemical compound C1=CC=C2NC(CCCO)=NC2=C1 CQFSGSFSOWEIGO-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FVZXYJDGVYLMDB-UHFFFAOYSA-N 3-pyridin-2-ylpropan-1-ol Chemical compound OCCCC1=CC=CC=N1 FVZXYJDGVYLMDB-UHFFFAOYSA-N 0.000 description 1
- BLYPSHVDSAPASP-UHFFFAOYSA-N 3-pyridin-2-ylpropanal Chemical compound O=CCCC1=CC=CC=N1 BLYPSHVDSAPASP-UHFFFAOYSA-N 0.000 description 1
- SZMLTFOLQWEQFJ-UHFFFAOYSA-N 3-quinolin-2-ylpropan-1-ol Chemical compound C1=CC=CC2=NC(CCCO)=CC=C21 SZMLTFOLQWEQFJ-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- AKGAWLVXZNQNHO-UHFFFAOYSA-N 4-pyrimidin-2-ylbut-3-yn-1-ol Chemical compound OCCC#CC1=NC=CC=N1 AKGAWLVXZNQNHO-UHFFFAOYSA-N 0.000 description 1
- JVBGAHYNGUWVAI-UHFFFAOYSA-N 4-pyrimidin-2-ylbutan-1-ol Chemical compound OCCCCC1=NC=CC=N1 JVBGAHYNGUWVAI-UHFFFAOYSA-N 0.000 description 1
- SSTUITSVIFKUBE-UHFFFAOYSA-N 4-pyrimidin-2-ylbutanal Chemical compound O=CCCCC1=NC=CC=N1 SSTUITSVIFKUBE-UHFFFAOYSA-N 0.000 description 1
- QCXSNTXJIYUSLC-UHFFFAOYSA-N 6-pyrimidin-5-ylhexan-1-ol Chemical compound OCCCCCCC1=CN=CN=C1 QCXSNTXJIYUSLC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000005937 allylation reaction Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- OTJZCIYGRUNXTP-UHFFFAOYSA-N but-3-yn-1-ol Chemical compound OCCC#C OTJZCIYGRUNXTP-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- WJYHCYBNUJVCEH-UHFFFAOYSA-N cyclohexane;ethoxyethane Chemical compound CCOCC.C1CCCCC1 WJYHCYBNUJVCEH-UHFFFAOYSA-N 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N diphenylacetic acid Chemical class C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
Description
Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is (are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from Cy-4alkyl, Cj_galkoxy, hydroxy, halogen, -NR3R%* and -coR8; where R3 ana gr? each represent a hydrogen atom or a Cy-4alkyl group or -NR3Rr% forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -0- or -S- or a group -NH- or -N(CH3)-: and
R8 represents hydroxy, Cj.galkoxy or -NR3R%; with the proviso that (i) when Het represents a pyridyl group substituted by the group -NR3R? or -cor® and Q is a chlorine atom, or (ii) when Het represents a pyridyl group optionally substituted by one or two groups selected from halogen, hydroxy, Cj-3alkyl and Cj-3alkoxy, and Y represents a bond or a Cj-4alkylene, Cp._galkenylene or Cay-galkynylene chain, then, in both cases, R represents a Ci-3alkyl group and/or at least one of the chains -XCHp~ and -CH,Y- is substituted by one or two Cj.jalkyl groups.
The compounds have a stimulant action at B2- adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as . asthma and chronic bronchitis.
pA
CHLOROANIL INE DERIVATIVES
This invention relates to chloroaniline derivatives having a : stimulant action at B,-adrenoreceptors, to processes for their : preparation, to pharmaceutical compositions containing them and to their use in medicine.
Chloroaniline derivatives have previously been described as bronchodilators having stimulant activity at p-adrenoreceptors.
Thus, British Patent Specification No. 1178191 describes compounds of the general structure
Hol ee R2
KN No erbores
HN x IE
Hal in which the substituents Hal represent bromine or chlorine atoms; R1 represents hydrogen or hydroxyl; R?2 and R3 each represent hydrogen or
C,-, alkyl; and RY and R® each represent hydrogen, Ci-¢ alkyl, ’ alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, dialkylaminoalkyl, . ] cycloalkyl, phenyl, benzyl or adamantyl radicals, or NRYRS forms a } 20 heterocyclic ring optionally substituted by €,_; alkyl groups.
UK Patent Specification Nos. 2165542A and 2182658A describe compounds of the general structure cl \ oo } «—e R
Co 25 er ei gc 00h van -— oH R2 ; ’ oY } in which R! and R2 each represent hydrogen or Ci-3 alkyl; X represents
Co 30 © C,-¢ alkylene, C,_¢ alkenylene or C,_. alkynylene; Y represents C,_, ‘ alkylene, Coy alkenylene or Com alkynylene; and Ar represents a phenyl group optionally substituted by one or more of a variety of specific substituents.
We have now found a novel group of compounds which differ structurally from those Geseribed in British Patent Specification No. 1178191 and IK Patent Specification Nos. 21655424 and 2182658A, and which have a desirable and useful profile of activity.
Thus the present invention provides compounds of the general formula (I) \ .“_.o R RI
ZN lo]
Me J CHINHEXCH DCI Yet (1) «<e orn R2 cf and physiologically acceptable salts and solvates (e.g. hydrates) thereof, wherein
Q represents a chlorine atom or a trifluoromethyl group;
X represents a bond, or a Cig alkylene, Cog alkenylene or Coe alkynylene chain, and
Y represents a band, or a Cie alkylene, Cog alkenylene or Cog alkynylene chain with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10, and the chains XCH, and
CH,Y may each be optionally substituted by one or two Ci; alkyl groups, or, when one carbon atom is substituted by two alkyl groups, these may be linked to form an alkylene group;
R represents a hydrogen atom or a Cis alkyl group;
Rl and R? each represent a hydrogen atom or a C3 alkyl group, with the proviso that the sum total of carbon atoms in R! and R? is not more than 4; and
Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) represent nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from Coy alkyl, Cy alkoxy, hydroxy, halogen, -NR3R% and -CORS; vhere R? and R" cach represent a hydrogen atom or a C1-yalkyl group or 3° -NR3R" forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -0- or -5- or a group -NH- or -N(CH 3) =; and
RS represents hydroxy, C,_, alkoxy or -NR3RY; : with the proviso that (i) when Het represents a pyridyl group ; 5 substituted by the group -NRIR* or -COR® and Q is a chlorine atom, or oh } (ii) when Het represents a pyridyl group optionally substituted by one goo o or two groups selected from halogen, hydroxy, C;_jalkyl and
Fi Cee C,-3elkoxy, and Y represents a bond or a C-yalkylene, C,_,alkenylene i) oo or C,_yalkynylene chain, then, in both cases, R represents a C;_3alkyl : 10 group and/or at least one of the chains -XCH,- and -CH,Y- is ‘ substituted by one or two C,_jalkyl groups. k It will be appreciated that the compounds of general formula (I) oo possess one or more asymmetric carbon atoms. The compounds according to the invention thus include all enantiomers, diastereoisomers and mixtures thereof, including racemates. Compounds in which the carbon atom in the -CH- group is in the R configuration are preferred.
OH
In the definition of general formula (1), the term alkenylene includes both cis and trans structures.
In the general formula (I), the chain XCH, may be for example “CH=, -(CHy),7, =(CHy) 3=, =(CHy) =, =(CH,) g-, =(CH,) (-, ~(CH,) ,-, -CH,C=CCH,~, ~(CH,) ,CH=CHCH,,-, -(CH,) ,C=CCH ,-, ~CH=CH(CH ,) ,-, ~CH=CH(CH, );- or -CH,C=C(CH,),~. The optionally substituted chain
CH,Y may be for example ~CH ,-, -(CH,) ,-, -(CH,) 5-, -(CH,) oy -(CHy)g~, =(CHy)g~, -CH(CH;)(CH,),=, -CH,CH=CH-, -CH,C=C=, -(CH,) ,CH=CH- or -(CH,),C=C-. - v bo Preferably the total number of carbon atoms ih the chains X and Y . is 4 to 10 inclusive. Compounds wherein the sum total of carbon atoms BE in the chains X and Y is 4, 5, 6, 7, B or 9 are particularly : preferred.
One preferred group of compounds of formule (I) is that in which
X represents a C3-,alkylene chain and Y represents a C,_calkylene r i chain. Particular compounds of this type are those wherein X ' 3 represents -(CH,),~ and Y represents ~(CH,) =, -(CH,), or -(CH,) 5-- ; 35 In the compounds of formula (1), R, R! and R2 may each be, for example, methyl, ethyl, propyl or isopropyl groups. If one of R! and
RZ is a propyl or isopropyl group, the other is a hydrogen atom or a methyl group. R, Rl and R? are cach preferably a hydrogen atom or a methyl group.
A preferred group of compounds are those in which R represents a hydrogen atom.
Another preferred group of compounds are those wherein R! and R2 are both hydrogen atoms, or R! is a hydrogen atom and R2 is a Ci-3 alkyl group, particularly a methyl group, or R! is a methyl group and
R? is a methyl group.
The group Het is attached to the rest of the molecule through any available position in the heteroaryl ring. Any substituent(d) in the group Het may be at any available position(s) in the benzene land/or the heteroaryl rings. Preferably tet represents a group selected from pyrimidinyl, pyrazinyl, triazinyl, thiszolyl, quinolinyl, benzimidezolyl, benzothiazolyl, benzoxazolyl and pyridyl.
A particularly preferred group of compounds of formula (I) is that in which Het represents a pyrimidinyl or thiazolyl group.
When the group Het is substituted by one or two halogen atoms, these may be chlorine, fluorine or bromine. When -NR3RY represents a saturated heterocyclic amino group, this may be, for example, a pyrrolidino, piperidino, hexamethyleneimino, piperazino,
N-methylpiperazino, morpholino, homomorpholino or thiamorpholino group.
Preferred compounds according to the invention are 4-amino-3,5- dichloro-a-[{[6-[4-(2-pyrimidinyl)butoxyJhexyllaminolmethyl] benzenemethanol; 4~amino-~3,5-dichloro-a~[[[6-[[6-(5~pyrimidinyl)hexylJoxy hexyl] amino Jmethyl]benzenemethanol; 4-amino-3,5-dichloro-a-[[[6-[[6-(2-pyrimidinyl)hexylJoxy Jhexyl] amino Jmethyllberzenemethanol ; 4-amino-3,5-dichloro-a-[[[6-[3-(2-thiazolyl)propoxy JhexylJamino] methyl Jbenzenemethanol; and their physiologically acceptable salts and solvates.
Suiteble physiologically accepteble salts of the compounds of general formula (1) include acid addition salts derived from inorganic and organic acids, such as hydrochlorides, hydrobromides, sulphates, :
phosphates, maleates, tartrates, citrates, henzoates, 4-methoxy- benzoates, 2- or 4-hydroxybenzoateg, 4-~-chlorobenzoates, benzene- sulphonates, p-tolucnesulphonates, naphthalenesulphonates, methanesulphonates, sulphamates, ascorbates, salicylates, acetates, diphenylacetates, triphenylacetates, adipastes, fumarates, succinates,
CL lactates, glutarates, gluconates, tricarballylates, hydroxy~naphthalenecarboxylates e.g. l-hydroxy- or 3-hydroxy-2- naphthalenecarboxylates, or oleates. The compounds may also form salts with suitable bases where appropriate. Examples of such salts are alkali metal (e.g. sodium and potassium) and alkaline earth metal (e.g. calcium or magnesium) salts, and salts with organic bases (e.g. triethylamine).
The compounds according to the invention have a stimulant action at f,-adrenoreceptors, which furthermore is of a particularly advantageous profile. The stimulant action was demonstrated in the isolated trachea of the guinea-pig, where compounds were shown to cause relaxation of contractions induced by PGF a or electrical . stimulation. Compounds according to the invention have shown a particularly long duration of action in these tests.
The compounds according to the invention may be used in the
Lo treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
So The compounds according to the invention are also indicated as oo i useful for the treatment of inflammatory and allergic skin diseases, . oo 25 congestive heart failure, depression, premature labour, glaucoma, and ; . ) in the treatment of conditions in which there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration. : Co The invention accordingly further provides compounds of formula . (I) end their physiologically acceptable salts and solvates for use in the therapy or prophylaxis of diseases associated with reversible airways obstruction in human or animal subjects.
The compounds according to the invention may be formulated for ] administration in any convenient way. The invention therefore includes within its scope pharmaceutical compositions comprising at least one compound of Formula (1) or a physiologically acceptable salt or solvate therenf formulated For use in human or veterinary medicine.
Such compositions may be presented for use with physiolngically acceptable carriers or excipients, optionally with supplementary medicinal agents.
S The compounds may be formulated in a form suitable for administration by inhalation or insufflation, or for oral, buceal, parenteral, topical (including nasal) or rectal administration.
Administration by inhalation or insufflation is preferred.
For administration by inhelatica the compounds according ta the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellant, such as dichlorodifluoramethane, trichlorofluoromethane, dichlorotetrafluorocthane, carbon dioxide or other suitable gas, or from a nebuliser. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in For example capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.
For oral administration, the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions,
Syrups or suspensions prepared by conventional means with acceptable excipients.
For buccal administration Lhe composition may take the form of tablets, drops or lozenges formulated in conventional manner.
The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations . for injection may be presented in unit dosage form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the , active ingredient may be in powder form for reconstitution with a suitable vehicle, e.q. sterile pyrogen-frec water, before use.
For topical administration the pharmaceutical composition may take the form of ointments, lotions or creams formulated in a conventional manner, with for example an aqueous or oily base, generally with the addition of suitable thickening agents and/or " solvents. For nasal application, the composition may take the form of a spray, formulated for example as an aqueous solution or suspension or as an aerosol with the use of a suitable propellant.
The compounds of the invention may also be formulated in recta. compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or : other glyceride.
Where pharmaceutical compositions are described above for oral, buccal, rectal or topical administration, these may be presented in a conventional manner associated with controlled release forms.
A proposed daily dosage of active compound for the treatment of man is 0.005mg to 100mg, which may be conveniently administered in one or two doses. The precise dose employed will of course depend on the age and condition of the patient and on the route of administration.
Thus a suitable dose for administration by inhalation is 0.005mg to Co . 20mg, for oral administration is 0.02Zmg to 100mg, and for parenteral administration is 0.0lmg to 2mg for administration by bolus injection ~ and 0.0lmg to 25mg for administration by infusion.
The compounds according to the invention may be prepared by a | Lo } number of processes. In the following description, Q, X, Y, Het, R, ’ : R! and R? are as defined for general formula (I) unless otherwise specified. In the preparation of both intermediates and end-products i the final step in the reaction may be the removal of a protecting group. Suitable protecting groups and their removal are described in general process (3) below.
In one general process (1), a compound of general formulq (I) may , be prepared by ‘alkylation. Conventional alkylation procedures may be used.
Thus, for example, in one process (a), a compound af general
Formula (I) in which RY is a hydrogen atom may be prepared by alkylation of an amine of general formula (Ln) “\ .__.o R
Ne YN, cndirses (11) \ lo ee OH of (wherein R® is a hydrogen atom or a protecting group and R® is a hydrogen atom) followed by removal of any protecting group where present.
The alkylation (a) may be effected using an alkylating agent of general formula (III): ae Het (111) (wherein L. is a leaving group, for example a halogen atom such as chlorine, bromine or iodine, or a hydrocarbylsulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy).
The alkylation is preferably effected in the presence of a suitable acid scavenger, for example, inorganic bases such as sodium or potassium carbonate, oryaniec bases such as triethylamine, diisopropylethylamine or pyridine, or alkylene oxides such ss ethylene oxide or propylene oxide. The reaction is conveniently effected in a solvent such as acetonitrile or an ether e.g. tetrahydrofuran or dioxan, a ketone e.g. butanone or methyl isobutyl ketone, a substituted amide e.g. dimethylformamide or a chlorinated hydrocarbon e.g. chloroform, at a temperature between ambient and the reflux temperature of the solvent.
According to another example (b) of an allylation process, a compound of general formula (1) in which R! represents a hydrogen atom : may be prepared by alkylation of an amine of general formula (11), as previously defined except that R® is a hydrogen atom or a group convertible thereto under the reaction conditions, with a compound of general formula (IV):
R2COXCH NCH, Y-tet (Iv) in the presence of a reducing agent, followed when necessary by removal . of any protecting groups. ) 5 Examples of suitable R® groups convertible into a hydrogen atom are arylmethyl groups such as benzyl, a-methylbenzyl and benzhydryl.
Suitable reducing agents include hydrogen in the presence of a catalyst such as platinum, platinum oxide, palladium, palladium oxide,
Raney nickel or rhodium, on a support such as charcoal, using an alcohol, e.g. ethanol or methanol, or an ester e.q. ethyl acetate, or an ether e.g. tetrshydrofuran, or water, as reaction sclvent, or a mixture of solvents, e.g. a mixture of two or more of those just described, at normal or elevated temperature and pressure, for example from 20 to 100°C and from 1 to 10 atmospheres.
Alternatively when one or both of R5 and R6é are hydrogen atoms, the reducing agent may be a hydride such as diborane or a metal hydride such as sodium borohydride, sodium cyanoborohydride or lithium aluminium hydride. Suitable solvents for the reaction with these . reducing agents will depend on the particular hydride used, but will include alcohols such as methanol or ethanol, or ethers such as diethyl
A ether or tert-butyl methyl ether, or tetrahydrofuran. : . , ‘Vhen a compound of formula (II) where RS and R® are each hydrogen atoms is used, the intermediate imine of formula (V) may be formed: , 25 nN [—— R
I Sethian foi tet (v) oe OH R2 cl
Reduction of the imine using the conditions described above, followed, where necessary, by removel of any protecting groups, gives a compound of general formula (1). . In another general process (2) compounds of Formula (1) may be prepared by reducing an intermediate of general formula (VI): - 1 - fo
Co :
il
No . Rt 7 \
Ney J EX AXEHL OCH Y He t (v1)
Tle R2 /
Cl wherein at least one of X1, X?, X and Y represents a reducible group and the other(s) take the appropriate meaning as Follows, which is x! is -CH(OH)-, X2 is —CHRNRS- (where RS represents a hydrogen atom or a protecting group), and X and Y are as defined in formula (1), followed where necessary by removal of any protecting groups.
Suitable reducible groups include those wherein X! is a group
Ye=0, X2 is a group -CHRNR”- (wherein R7 represents a group convertible to hydrogen by catalytic hydrogenation, for example an arylmethyl group such as benzyl, benzhydryl or a-methylbenzyl).
The reduction may be effected using reducing agents conveniently employed for the reduction of ketones or protected amines.
Thus, for example, when X! in general formula (VI) represents a
Je=0 group this may be reduced to a -CH(OH)- group using hydrogen in the presence of a catalyst such as platinum, platinum oxids, palladium, palladium oxide, Raney nickel or rhodium, on a support such as charcoal, using an alcohol e.q. ethanol, an ester e.g. ethyl acetate, an ether e.q. tetrahydrofuran, or water, as reaction solvent, or a mixture of solvents, e.g. a mixture of two or more of those Just described, at normal or elevated temperature and pressuré, for example from 20 to 100°C and from 1 to 10 atmospheres. Alternatively, the reducing agent may be, for example, a hydride such as diborane or a metal hydride such as lithium aluminium hydride, sodium bis(2-methoxyethoxy) aluminium hydride, sodium borohydride or aluminium hydride. The reaction may be effected in an appropriate solvent, such as an alcohol e.q. methanol or ethanol, or an ether such as tetrahydrofuran, or a halogenated hydrocarbon such as dichloromethane.
¥hen X2 in general formula (VI) represents a ~CHRNR 7 ‘ group this may be reduced to a -CHRNH- group using hydrogen in the presence of a catalyst as described above.
Co Co Where it is desired to use a protected intermediate of general pe . 5 formula (VI) it is particularly convenient to use a protecting group ol a RS which is capable of being removed under the reducing conditions, for example hydrogen and a catalyst, thus avoiding the need for a separate deprotection step. Suitable protecting groups of this type i include arylmethyl groups such as benzyl, benzhydryl and a-methylbenzyl.
In the above reduction process, and also in the preparation of intermediates, care must be taken to avoid the use of hydrogen and a catalyst when products are required in which X and/or Y represent alkenylene or alkynylene groups.
In a further process (3) compounds of formula (I) may be prepared by deprotecting an intermediate of general formula (vin) \ — R RL 7 \
HoN—ey + HICHNROGXCH ,0CH )Y-Het (VII) b <=e OH R2 : er wherein RS is a protecting group and/or the group Het contains a : protecting group. oo
The protecting group may be any conventional protecting group as : described for example in "Protective Groups in Dfganic Chemistry", by
Theodora Greene (John Wiley and Sons Inc, 1981). Thus, for example, hydroxy groups may be protected by arylmethyl groups such as benzyl, ' diphenylmethyl or triphenylmethyl, hy acyl groups such as acetyl, or as tetrahydropyraenyl derivatives. Examples of suitable amino : ’ protecting groups include arylmethyl groups such as benzyl, a-methylbenzyl, diphenylmethyl or triphenylmethyl, and acyl groups such as acetyl, trichloroacetyl or trifluoroacetyl.
The deprotection to yield a compound of general formula (I) may be effected using conventional techniques. Thus for example arylmethyl groups may be removed by hydrogenolysis in the presence of a metal catalyst (e.g. palladiom on charcoal). Tetrahydropyranyl groups may be cleaved by hydrolysis onder acidic condil ions. Acyl groups may ho removed by hydrolysis with an acid such as a mineral acid e.g. hydrochloric acid, or a base such as sodium hydroxide or potassium carbonate, and a group such as trichloroacetyl may be removed hy reduction with, for example, zin: and acetic acid.
Intermediates of formula (VI) for use in the reduction process (2) in which X! is the group p= may he prepared by reaction of a haloketone of formula (VIII) | \ — R non Nobel (VIII)
TN
«e cr’
LS (where tal represents a halogen atom e.g. bromine) with an amine of formula (IX) it
RSNICXCH OCH YV-Het (IX) v2 (where RS is a hydrogen atom or a group convertible thereto by catalytic hydrogenation).
The reaction may be effected in a cold or hot solvent, for example tetrahydrofuran, tert-butyl methyl ether, dioxan, chloroform, dichloromethane, dimethylformamide, acetonitrile, a ketone such as butanone or methylisobutylketone, or an ester such as ethyl acetate, preferably in the presence of a base such as diisopropylethylamine, sodium carbonate or other acid scavenger such as propylene oxide.
Intermediates of general formula (VI) in which X! is the group
Ses may be reduced to the corresponding intermediate in which X! is the group -CH(OH)- using for example a metal hydride such as sodium borohydride in a solvent e.g. ethanol, methanol and/or tetrahydrofuran.
Amines of formula (11) and haloketones of formula (VIII) are either known compounds or may be prepared by methods analogous to those described for the preparation of known compounds. n Suitable methods for preparing intermediates of formulae (III), 0 5 (IV) and (IX) are described in UK Patent Specifications Nos. 2140800A
H and 2159151A end in the exemplification included hereinafter. oo In the general processes described above, the compound of formula
Co (1) obtained may be in the form of a salt, conveniently in the form of . a physiologically acceptable salt. Where desired, such salts may be converted to the corresponding free bases using conventional methods.
Physiologically acceptable salts of the compounds of general formula (I) may be prepared by reacting a compound of general formula (I) with an appropriate acid or base in the presence of a suitable solvent such as acetonitrile, acetone, chloroform, ethyl acetate or an alcohol, e.g. methanol, ethanol or isopropanol.
Physiologically acceptable salts may also be prepared from other salts, including other physiclogically acceptable salts, of the ) compounds of general formula (I), using conventional methods.
When a specific enantiomer of a compound of general formula (I) is required, this may be obtained by resolution of a corresponding racemate of a compound of general formula (I) using conventional methods. :
Thus, in one example an appropriate optically active acid may be : Co used to form salts with the racemate of a compound of general formulas (I). The resulting mixture of isomeric salts may be separated for i example by fractional crystallisation, into the diastereoisomeric salts from which the required enantiomer of a compound of general formula (I) may be isolated by conversion into the required free base. oo 30 Alternatively, enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates . using any of the general processes described herein. : Specific diastereoisdmers of a compound of formula (I) may be obtained by conventional methods for examplé, by synthesis from an appropriate asymmetric starting material using any of the processes described herein, or by conversion of a mixture of isomers of a compound of general formula (I) into appropriate diastereoisomeric derivatives e.g. salts which then can be separated by conventional means e.g. by fractional crystallisation.
The following examples illustrate the invention. Temperatures are in 9C. 'Dried' refers to drying of organic extracts using magnesium sulphate or sodium sulphate. Unless otherwise stated, thin layer chromatography (t.l.c.) was carried out on silica and flash column chromatography (FCC) on silica (Merck 9385) using one of the following solvent systems : A-toluene:ethanol:0.88 ammonia,
B-toluene:ethanol:triethylamine, C-diethyl ether:methanol. The following abbreviations are used : THF - tetrahydrofuran, OMF - dimethylformamidé, BTPC - bis(triphenylphosphine)palladium (11) chloride, TAB ~ tetra-n-butylammonium hydrogen sulphate, DEA -
N,N-diisopropylethylamine.
Intermediate 1 is 1-(4-amino-3,5-dichlorophenyl )-2-bromoethanone .
Intermediate 2 is 4-amino-a-(aminomethyl)-3,5-dichlorobenzenemethanol.
Intermediate 3 4-(2-Pyrimidinyl)-3-butynol
A mixture of 2-bromopyrimidine (5.0g), 3-butynol (2.20q), dicyclohexylamine (6.879), copper (I) iodide (50mg), BTPC (380mg) and acetonitrile (50mf) was stirred at room temperature under nitrogen for 16h. Ether (150m2) was added, the mixture filtered and the filtrate evaporated in vacuo. Purification of the residue by FCC eluting with ether and ether-methanol (1-3%) followed by System C (5:1) afforded the title compound as a pale yellow solid (4.29g) m.p. 58-640, t.1.c. (System C, 99:1) Rf 0.08
Intermediate 4 6-(2-Pyrinidinyl)-5-hexynol : A mixture of 2-bromopyrimidine (3.96g), S5-hexynol (2.44g), dicyclohexylamine (4g), BTPC (250mg), copper (1) iodide (25mg) and acetonitrile (40mR) was stirred abt ambient temperature under nitrogen for 1h (temp. rose to ~45%). Fther (120m) was added, the mixture was filtered and the filtrate was evaporated in vacuo to an oil which was 3 purified by FCC. Clution with ether followed by System C (17:3) gave g the title compound as a pale yellow oil (3.64q), t.l.c. (System C id cs 17:3) Rf 0.34.
RE Intermediate 5 : 6-(5-Pyrimidinyl)-5-hexynol
A mixture of S-bromopyrimidine (3.969), S5-hexynol (2.44q), dicyclohexylamine (4g) and acetonitrile (50m2) was de-oxygenated by bubbling nitrogen through the solution for 10min. BTPC (150mg) and copper (I) iodide (25mg) were added and the mixture was heated to 60-700 under nitrogen for lh, cooled and evaporated in vacuo. Ether (175m) was added, the mixture filtered and evaporated in vacuo and : the residue purified by FCC. Elution with ether followed by System C (19:1-92:8) gave the title compound as a pale yellow oil (3.79q), t.l.c. (System C (17:3) Rf 0.55.
Intermediate 6 2-Pyrimidinebutanol bras ot nessa
Stn 20 eg (2-Pyrimibing 1) <3: bubyiol (159) in “ethanol “(4Bni) was added to pre-reduced 10% palladium on charcoal (50% aqueous paste) in ethanol (60m) and hydrogenated at room temperature and atmospheric pressure.
The catalyst was removed by filtration through hyflo and the solvent evaporated in vacuo. The residual oil was purified by FCC. Elution with System C (19:1) and (9:1) gave the title compound as a pale yellow oil (1.32g)
Analysis Found: C,63.1; H,7.7; N,18.1.
CgHy,N,0 requires C,63.1; H,7.95; N,18.4%.
Intermediate 7 . 2-Pyrimidinehexanol : A solution of 6~(2-pyrimidinyl)-S-hexynol (3.099) in ethanol : (100mg) wast added to a pre-hydrogenated suspension of 10% palladium on charcoal (1.05g) in ethanol (50m) and hydrogenated at room temperature and pressure, filtered and evaporated in vacuo. The residual oil was purified by ICC eluting with ether and System C (99:1-85:15) to give the title compound as a pale yellow oil (0.93q).
Analysis ound: C,66.485 1,91; Ny15.6;
CiglygN,0 requires C,66.6; H,8.95; N,15.5%
Intermediate 8 5-Pyrimidinehexanol
A solution of 6-(5-pyrimidinyl)-5-hexynol {(3.52g) in ethanol (20m) was added to a pre-hydrogenated suspension of 10% palladium on carbon (1g) in ethanol (130m%) and hydrogenated at room temperature and pressure. The mixture was filtered through hyflo and the filtrate evaporated in vacuo to nive the title compound as a pale yellow oil (3.384).
Analysis Found: C,66.6; 11,9.0; N,15.2;
Cot eN,0 requires €,66.6;5 H,8.95; N,15.5%.
Internediate 9 1-(Phenylmethyl)-2-benzimidazolepropanol
A mixture of 2-benzimidazolepropanol (3.52qg), benzyl bromide (2.38m) and anhydrous potassium carbonate (5.52qg) in acetonitrile (57m1) was stirred at reflux far 4h, after which time more benzyl bromide (0.24mt) was added. The mixture was stirred at reflux for a further 2h, cooled, diluted with water (200m), extracted with ethyl acetate (2x100m2) and the organic extracts dried and evaporated in vacuo to give an orange oil. Purification by FCC eluting with System
B (98:2:1) gave a colourless oil (4.3g) which solidified on standing to give the title compound as a white solid (4.3g), t.l.c. (System A 40:10:1) RF 0.41.
Intermediate 10 2-Benzoxazoleethanol
A mixture of 2-methylbenzoxazole (4.0g) and paraformaldehyde (1.35q) was heated at 1400 with stirring in a 25m2 autoclave for 3h. ’
The mixture was cooled and the residue purified by I'CC. Elution with hexane-ether (2:1-1:1) followed by ether and ether-methanol (1-5%) afforded a product (1.89) which was distilled b.p. 165-1709/0.4mmltg
(Kugelrohr) to give the title compound as a colourless solid (1.226qg) m.p. 47-520, t.l.c. (ether) Rf 0.73. d Intermediate 11 wo 5 2-[4-[(6-Bromohexy1)oxy butyl Jpyrimidine : A mixture of 2-pyrimidinebutanal (1.319), 1,6-dibromohexane (5m2), 50% aqueous sodium hydroxide solution (5mf) and TAB (140mg) was _. vigorously stirred under nitrogen at 23% for 20h. Ether (25mg) and water (20mf) were added, the organic phase separated, washed with brine (20mg), dried and evaporated in vacuo. The residue was purified by FCC. Elution with hexane and hexane-ether (9:1) followed by ether afforded the title compound as a colourless oil (1.67q)
Analysis Found: C,53.3; H,7.2; N,8.9.
Cy, Hy3BIN,0 requires C,53.3; H,7.3S; N,8.9%.
Intermediate 12 4-02-[(6-Bromohexyl)oxyJethyl]-2-methylthiazole
A mixture of 2-methyl-4-thiazoleethanol (2.229), 1,6- dibromohexane (7.1mg) 12.5M aqueous sodium hydroxide (4m2) and TAB (0.1g) was stirred rapidly at room temperature for 16h. The reaction mixture was diluted with water (30m2), extracted with ether (3x30m2) and the combined organic extracts were washed with water (30m) and brine (30m), dried and concentrated. The residual oil was purified by FCC eluting with diethyl ether-hexane (1:3) to give the title compound as an orange oil (2.21g), t.l.c. (ether - hexane 1:3) Rf 0.17
Intermediate 13 2-[2-[(6-Bromohexy1)oxyJethylJbenzoxazole
A mixture of 2-benzoxazoleethanol (1.4649), 50% sodium hydroxide } (3m), 1,6-dibromohexane (3m2), TAB (100mg) and dichloromethane (2m) . was vigorously stirred at room temperature for 22h, diluted with water (15me) and extracted with ether (40mL). The organic phase was washed with brine (10mg), dried and evaporated in vacuo. The residual oil was purified by FCC. Elution with hexane and hexanc-ether (19:1)
followed by hexane-ether (2:1) and ether gave the title compound as a pale yellow oil (1.60q) which solidified on refrigeration.
Analysis Foun: C,50. 8; 11,6.0; N, 4.35.
CgHygBrNO, requires €,55.2; H,6.2; N,4.3%.
Intermediate 14 2-[6-[(6-Bromohexyl)oxy Jhexyllpyrimidine
A mixture of 2-pyrimidinehexanol (1.18q), 1,6-dibromohexane (4me), 50% sodium hydroxide (4m2) and TAB (100mg) was vigorously 1c stirred at room temperature for 17h, then diluted with water (40m) and ether (50mg). The organic phase was dried and evaporated in vacuo to an oil which was purified by FCC. Flution with hexane followed by hexane-ether (1:1) gave the title compound as a colourless oil (670mg), t.l.c. (ether) Rf 0.24
Intermediate 15 5-16-[(6-Bromohexyl)oxyJhexyllpyrimidine
A mixture of S-pyrimidinehexanol (1.82g), 50% sodium hydroxide (6m2), 1,6-dibromohexsne (6m%) and TAB (150mg) was vigorously stirred at room temperature for 3Dh then diluted with water (20mf) and ether (25m). The organic phase was dried and evaporated in vacuo. The residue was purified by FCC eluting with hexane followed by hexane-ether (1:1) and ether, to give the title compound as a colourless liquid (2.21g), t.l.c. (ether) Rf 0.35.
Intermediate 16 2-12-[ (5-8romopentyl)oxylethyllquinoline 2-(2-Hydroxyethy l)quinoline (2.00q), TAB (200mg) and 1,5-dibromopentane (8m) were dissolved in dichloromethane (6m) and 50% aqueous sodium hydroxide (8m) added. The mixture was vigorously stirred at room temperature for 26h, diluted with water (50m2) and extracted with diethyl ether (2x30m2). The organic extracts were dried, filtered and evaporated in vacuo to afford an oil, which! was purified by FCC eluting with cyclohexane-ether (1:1) and ether, to give the title compound as a yellow oil (2.67g), t.l.c. (ether) Rf 3.40.
— —
Intermediate 17 2-(3-[ (5-Bromopentyl)oxyJpropyll-1-(phenylmethyl)benzimidazole
A mixture of 1-(phenylmethyl)-2-benzimidazolepropanol . (3.0g), 1,5-dibromopentane (7.77g), TAB (0.5q) and 40% sodium + 5 hydroxide (5m2} in dichloromethane (10mf) was stirred at room temperature for 6h under nitrogen. The mixture was diluted with water " (100mg) and extracted with dichloromethane (2x100mf). The dried extracts were evaporated in vacuo to give an oil. Purification by FCC eluting with hexane-ether (10:0+0:10) gave the title compound as a colourless oil (0.98qg).
Analysis Found: C,63.30; H,6.54; N,6.76. ) C,,l,,BIN,0 requires C,63.61; 1,6.55; N,6.74%.
Intermediate 18 2-[3-[ (5-Bromopentyl)oxylpropyl]-1H-benzimidazole
A solution of 2-[3-[(5-bromopentyl)oxylpropyl]-1-(phenylmethyl) benzimidazole (1.7g) in absolute ethanol (20m%) containing 1:9 conc. hydrochloric acid:ethanol (3.27m%) was hydrogenated over pre-reduced 10% palladium oxide on charcoal catalyst (3Q0Omg) in ethanol (5m2) until the uptake of hydrogen (10lm2) ceased. The mixture was filtered . through hyflo and evaporated in vacuo to give an oil, which was dissolved in ether (150m) and washed with 8% sodium bicarbonate solution (100mg), dried end evaporated in vacuo to give an oil.
Purification by FCC eluting with hexane-ether (2:3+0:5) gave the title oo 25 compound as a yellow oil (0.92g). ) Analysis found: C,55.1; H,6.55; N,B.6.
C,sH,,BIN,0 requires C,55.4; H,6.5; N,B8.6%.
Intermediate 19 } 30 N-[6-[2-(2-Benzoxazolyl)ethoxylhexyl]benzenemethanamine : , : - A solution of 2-[2-[{6-bromohexyl)oxylethyl]lbenzoxazole (1.55q) in benzylamine (6mt) was heated at 125% for 2h under nitroger, cooled, } ! diluted with ether (100m%) end the ether suspension washed with 8% sodium bicarbonate solution (25m). The organic phase was dried and evaporated in vacuo. Benzylanine was removed by bulb to bulb distillation (b.p. 130%/25mm) to leave a product which wes purified by ’ ! » - 21 - wooo chramatography over silicon (Hercic ol) elaling vith Syastom 8 (82:10:10) to afford the title compound as a red oil (250mg), t.l.c. (System A 39:10:1) RF 0.55.
Intermediate 20 4-Amino-3,5-dichloro-a-{{[6-[2-(2-benzoxazolyl)ethoxy Jhexyl] {phenylmethyl)aminolmethyl]benzenemethanol
A solution of Intermediate 1 (1.16g), N-[6-[2-(2-benzoxazolyl) ethoxy JhexylJbenzenemethananine (1.469) and DEA (0.78m%) in THF (50m) was allowed to stand for 6h, then filtered and evaporated in vacuo.
The residual gum in methanol (20m%) was cooled to 0-59 and sodium borohydride (650mg) added portionwise over 0.5h. After a further 0.5h at 50 the solution was evaporated in vacuo and the residue partitioned between water (30mf) and ethyl acetate (60m2). The organic phase was dried and evaporated in vacuo to a gum. The residue was purified by
FCC eluting with hexane-ethyl acetate-triethylamine (60:40:1) to give the title compound as a pale yellow oil (1.10g), t.l.c. (hexane- ethyl acetate 2:1) RF 0.21.
Intermediate 21 : 2-[2-[ (6-Bromohexyl)oxylethyl]pyridine
A mixture of 2-pyridineethanol (5g), 1,6-dibromohexane (20m%), 50% (w/v) sodium hydroxide (20mg) and TAB (500mg) was stirred at room temperature for 6h. Water (100m) was added and the mixture was extracted with ether (2 x 100mg). The organic extracts were washed with water and brine, dried and concentrated to an oil which was purified by FCC eluting with hexaneshexane-ether (1:1) to give the title compound as a colourless oil (6.6g), t.l.c. (hexane-ether 1:1)
Rf 0.19.
Intermediate 22
N-16-[2-(2-Pyridinyl)ethoxy Ihexyl]lvenzenemel hanamine
Bh 2-[2-[ (6-Bromohexyl)oxy Ji:thyllpyridine (6.3) ‘was added to benzylamine (20m2) at 140% under nitrogen. After lh at 1409 the reaction mixture was cooled and partitioned between 2H sodium hydroxide (100m) and ether (100mZ). The organic layer was washed - 22 -
S—
RAD ORIGINAL P with water and brine, dried and concentrated to a yellow oil. The excess benzylamine was removed by distillation under reduced pressure } Ce to leave the title compound as a yellow oil (6.8g), t.l.c. (System A
Ca 80:20:2) RF 0.44.
Ls a Co Intermediate 23 4-Amino-3,5-dichloro-a-[1-[ (phenylmethyl)[6-({2-(2-pyridinyl)ethoxy] hexylJamino]ethyl]benzenemethanol
A solution of 1-(4-amino-3,5-dichlorophenyl)-2-bromopropanone : 10 (1.12qg), N-[6-[2-(2-pyridinyl)ethoxylhexylJbenzenemethanamine (1.18g) and DEA (0.92me) in THF (20m2) was heated at reflux for 20h under nitrogen, then cooled to 0-59 for lh. The mixture was Filtered and the filtrate evaporated in vacuo to a dark oil which was taken up in methanol (20me) and cooled to 0-50. Sodium borohydride (570mg) was added portionwise over 20 min, the solution allowed to warm to 200 over 2h and evaporated in vacuo. The residue was partitioned between water (50m) and ethyl acetate (100m2) and the organic phase dried and evaporated in vacuo to a qum. Purification by FCC eluting with hexane-ethyl acetate (2:1-1:1) gave the title compound as a colourless gum (680mg), t.l.c. (hexane-ethyl acetate 2:1) Rf 0.15.
Intermediate 24 a-Methyl-2-pyridinepropanol
Dimethyl sulphoxide (3.3m) was added dropwise to a solution of oxalyl chloride (3.9m2) in dichloromethane (25m%) at ~78°% under nitrogen. After gas evolution had ceased (5min) a solution of 2-pyridinepropanol (4.09) in dichloromethane (20m) was added over 5min and the solution stirred at -78% for 20min. Triethylemine (5m) was added dropwise to the solution, then the resulting dark green mixture warmed to 209 and washed with 2M sodium carbonate solution (20m). The organic phase was dried and evaporated in vacuo to give 2-pyridinepropanal. This aldehyde was immediately dissolved in THF (30m2) and edded dropwise to a 3H solution of methylmagnesium chloride in THF (20mg) at 0-5% under nitrogen. After lh, water (10m%) was cautiously added followed by sufficient 2H hydrochloric acid to dissolve all the magnesium residues (resulting pi~7). The solution was extracted with dichloromethane (3 x 30m) and the organic extracts dried and evaporated in vacuo to a dark oil. Kugelrohr bulb to bulb distillation (b.p. 130-135%/0.7mm) afforded the title compound as a pale yellow oi! (0.91g), t.l.c. ethyl acetate Rf 0.17.
Intermediate 25
N-[6-[1-Methyl-3-(2-pyridinyl)propoxylhexyl]benzenemethanamine - A mixture of a-methyl-2-pyridinepropanol (0.62qg) 1,6-dibromohexane (4mg), 50% sodium hydroxide (4mf) and TAB (50mg) was vigorously stirred at 500 for 6h, cooled and diluted with water (15m2) snd ether (100mg). The ether extract was dried and evaporated in vacuo to an oil which was partitioned between 2N hydrochloric acid (60mg) and hexane (2x25m%). The acidic aqueous phase was basified with 40% sodium hydroxide to pHl2 and extracted with ether (2x50m2).
The ethereal extracts were dried and evaporated in vacuo to give 2-[3-[(6-bromohexyl)oxy]-1- methylpropyllpyridine (360mg) as a : colourless oil. This was dissolved in benzylamine (4m), and heated at 1259 for 2h under nitrogen, cooled and combined with an earlier reaction product (from 0.28yg of the bromo compound) and partitioned hetween B% sodium bicarbonate solution (40m) and ether (100m). The ether phase was dried and evaporated in vacuo. Benzylamine was removed by distillation in vacuo (Kugelrohr 1509/25mm) to leave the title compound as a yellow oil (0.68g), t.l.c. (System A 39:10:1) Rf 0.36. :
Intermediate 26 4-Amino-3,5-dichloro-a-[[[6-[1-methyl-3-(2-pyridinyl)propoxyJlhexyl]- (phenylmethyl)amino]methyl]benzenemethanol
A solution of Intermediate 1 (0.6g) and DEA (0.55m%) in THF (20m2) was treated with ‘N-[6-[1-methyl-3-(2-pyridinyl)propoxy]- hexyl Jbenzenemethanamine (0.729) and the solution allowed to stand for 7h, then filtered and evaporated in vacuo. The residue in methanol (15m2) was cooled to 0-59 and sodium borohydride (0.42g, 11.1lmmol) added portionwise over 20min. After lh, the solution was evaporated in vacuo and the residue partitioned between water (15mf) and ethyl acetate (60mf). The organic phase was washed with brine (10mf), dried and evaporated in vacuo to a pale yellow gum which was purified by FCC eluting with hexane-ethyl acetate-triethylamine (66:33:1) to give the title compound as a pale yellow gum (0.91g), t.l.c. (diethyl ether) a. Rf 0.38.
Cs
Cyc Intermediate 27 dire cE © [6-[(6-Bromohexyl)oxyl-1-hexynyllpyrazine
Alp ee ~ A mixture of bromopyrazine (1.64g), 6-[(6-bromohexyl)oxy]-1-hexyne
Sa oo ; (2.69g) N,N-dicyclohexylamine (1.88g), BTPC (130mg) and copper (I)
Sh 10 iodide (13mg) in acetonitrile (30mi) was stirred at 220 under nitrogen
Co for lh. Ether (150mg) was added, the mixture filtered and evaporated oo in vacuo to an oil which wes purified by FCC eluting with hexane-ether (3:2 » 1:1) followed by ether to give the title compound as a dark yellow oil (2.79q), t.l.c. (ether) Rf D.5.
Intermediate 28 [6-[ (6-Bromohexyl)oxyJhexyllpyrazine
A solution of [6-[(6-bromohexyl)oxyl-l-hexynyllpyrazine (2.76g) in ethanol (70mt) was added to a pre-hydrogenated suspension of 10% : © 20 palladium on carbon (2.00g) in ethanol (50m%) and hydrogenated at room temperature and pressure for 1lh. The mixture wes filtered through
I .. hyflo end evaporated in vacuo to afford the title.compound ag.a* ™ ". ~~ '%7 "0 3 colourless oil (2.45g), t.l.e. (ether) Rf 0.55.
Intermediate 29 3-{(2-Thiazolyl)]-2-propynol
Copper (I) iodide (28.5mg) was added to a stirred solution of 2-bromo- thiazole (5g), propargyl alcohol (1.68g), BTPC (210mg) and DEA (2.41q) i in acetonitrile (88m&). The mixture was stirred under nitrogen for
BOh, concentrated and partitioned between ethyl acetate (100mg) and i water (100mf). The organic layer was dried and concentrated to yield . : the crude product which was purified by FCC eluting with toluene/ethyl ] acetate (5:2) to give the title product ss a brown oil (0.68g), 4 - t.l.c. (toluene/ethyl acetate 2:1) Rf 0.27. io 35
ANE j - { _ 25 - oo “
- ! *
Intermediate 30 i 2-Thiazolepropanol
Glacial acetic acid (16m) was added dropwise during 0.25h to a stirred solution of 3-(2-thiazolyl)-2-propynol (2.4q) and dipotassium ‘ 5 azodicarboxylate (50g) in pyridine (200m%). The mixture was stirred : at room temperature for lh and additional glacial acetic scid (40mg) ’ ; . added during 0.5h. The mixture was stirred at room temperature for 2 days. The solvent was removed by azeotropic distillation with toluene (2x100m2) and the residue partitioned between water (100m2) and ethyl acetate (100mt). The aqueous layer was extracted with ethyl acetate (2x50m2) and the combined extracts dried and evaporated to leave a brown oil. This was purified by FCC eluting with toluene:ethyl i acetate:triethylamine (50:50:1) to give the title compound as an orange oil (1.45g), t.l.c. (toluene:ethyl acetate:triethylamine 50:50:1) Rf 0.15.
Intermediate 31 2-[[(6-Bromohexyl)oxylpropyl]thiazole
A mixture of 2-thiazolepropanol (1.45g) 1,6-dibromohexane (7.4qg), TAB (125mg) and 50% w/v sodium hydroxide solution (5mf) was stirred at room temperature for 6h, diluted with water (50m%) and extracted with ether (3x50mf). The combined, dried extracts were evaporated and the residue was purified by FCC eluting with toluene followed by System B (98:2:1), to give the title compound as a pale yellow oil (1.76qg), t.l.c. (System B 95:5:1) Rf 0.55.
Intermediate 32 6-[ (6-Bromohexyl)oxy]-1-hexyne
A mixture of 5-hexyn-l-ol (5g), 1,6-dibromohexane (37.29g), TAB (lg) and 50% sodium hydroxide solution (20mg) was stirred under nitrogen for 22h. The mixture was diluted with water (100m) and extracted with diethyl ether (2 x 150m&). The combined organic extracts were } dried and evaporated in vacuo to give an cil. Purification by FCC eluting with hexane followed by hexane:ether (95:5) gave the title compound as a colourless nil. (7.7g), t.l.c. {(hexane:ether 2:1) Rf 0.80. . - 26 -
J
Intermediate 33 2-[6-[(6-Bromohexyl)oxy]-1-hexynyllquinoline
A mixture of 2-bromoquinoline (3.00g), 6-[(6-bromohexyl)oxy]-1-hexyne (3.77g), BTPC (90mg), copper (I) iodide (1lmg) and dicyclohexylamine (2.799) in acetonitrile (35mf) was stirred at room temperature under - nitrogen for 20h. The mixture was diluted with ether (90mg), filtered and the filtrate evaporated in vacuo to give a brown oil.
Purification by FCC eluting with hexane:ether (4:1 + 2:1) gave the title compound as a brown oil (4.25g), t.l.c. (hexane:ether 2:1) Rf 0.22. .
Intermediate 34
N-[6-[[6-(2-Pyridinyl)-5-hexynyl]oxylhexy! Jbenzenemethanamine
A mixture of 2-bromopyridine (2.67g), 6-[(6-bromohexyl)oxy]-l-hexyne (4.41g), BTPC (105mg), copper (I) iodide (13mg) and N,N- dicyclohexylamine (3.37g) in acetonitrile (40mf) was stirred at room temperature under nitrogen for 20h. The mixture was diluted with h ether (100m), filtered and the filtrate evaporated in vacuo to give e brown oil. Purification by FCC eluting with hexane:ether (9:1 + 1:1) gave a brown oil (4.59g) which was heated with benzylamine (13.8m%) at 1009 for 2.5h. The mixture was washed with B% sodium bicarbonate solution (75m2) and ether (75m2). The combined organic extracts were dried and evaporated in vacuo and excess benzylamine was removed by : distillation in the Kugelrohr apparatus to leave the title compound as a brown oil. (3.60g), t.l.c. (System A 40:10:1) Rf 0.58. :
Intermediate 35 4-Amino-3,5-dichloro-a-[{ (phenylmethyl)[6-[[6-(2-pyridinyl)-5- hexyny1]oxy Jhexyl]amino]lmethyl]benzenemethanol "A solution of l-[4-amino-3,5-dichlorol-2-bromoethanone (0.93g) and
N-[6-[[6~(2-pyridinyl)-5-hexynylloxy Jhexyllbenzenemethanamine (1.29) in THF (30mg) was stirred under nitrogen for 20h. The mixture was . filtered and the filtrate evaporated in vacuo to give an oil. The oil was dissolved in methanol (25m) and dichloromethane (35m2) and sodium borohydride (0.51g) added portionwise to the solution at 00 under nitrogen. The solution was stirred at room temperature for 1h, then carefully diluted with water (12m%) and evaporated in vacuo. The residue was partitioned between ethyl acetate (100m%) and water (100me), the aqueous phase was re-extracted with ethyl acetate (100mg) and the combined organic fractions dried and evaporated in vacuo to give a brown oil. Purification by FCC eluting with } hexane:ethyl acetate (1:1) gave the title compound as an orange-brown
Eh oil (1.65g), t.l.c. (hexane:ethyl acetate 1:1 on 2% triethylamine
Ts doped plate) Rf 0.61. Co
Intermediate 36 2-[3-{ (6-Bromohexy1)oxyIpropyllyuinoline 2-Quinolinepropanol (0.92g), 50% aqueous sodium hydroxide (Sm%), 1,6-dibromohexane (5m) and TAB (57mg) were vigorously stirred at 210 for 6h. The mixture was diluted with water (25m%) and ether (100m%) and the organic phase dried and evaporated in vacuo. The residue was purified by FCC with hexane eluant to remove 1,6-dibromohexane.
Elution with ether afforded the title compound as a yellow oil (0.88g), t.l.c. ether Rf 0.51.
Example 1 4-Amino-3,5-dichloro-a-[{[6-{4-(2-pyrimidinyl)butoxy]hexyl]amino]- methyl]lbenzenemethanol
A mixture of Intermediate 2 (0.84g), 2-{4-[(6-bromohexyl)oxy] butyllpyrimidine (0.80g), DEA (0.53m%) and DMF {(10m2) was heated at
CTY 28 1600 Fer 1h under nitrogen. The solution was cboled, evaporated in = ' vacuo, end the residue purified by FCC eluting with System A (88:10:1). The resulting product was dissolved in hot isopropanol . (15m&) containing fumaric acid (90.5mg), cooled and kept at 0° for 1h
The crystalline, hygroscopic hemifumarate salt was collected by - 30 filtration. The mother liquors deposited a second crop which was combined with the first crop, and partitioned between 8% sodium ' bicarbonate solution (60m) and ethyl acetate (2x60mf). The combined . : organic extracts were dried and evaporated in vacuo to a gum. ’ 35 ¢
Co . - 28 -
a —
Trituration with hexane (20m) for 24h afforded the title compound as a colourless powder (440mg), m.p. 77-799, t.l.c. (System A 39:1N:1) Rf 0.46.
Analysis Found: C,57.5; H,7.2; N,12.0; Cl,15.6.
C,,H3,C1,N,0, requires C,58.0; 1,7.15 N,12.3; £1,15.6%. ne Examples 2-4 were prepared in a similar manner from Intermediate 2 and the appropriate bromo compound.
Exemple 2 4-Amino-3,5-dichloro-a-[ [[5-(2-quinolinylethoxy)pentylJamino]methyl]- benzenemethanol, (E)-butenedioate salt (2:1)
From Intermediate 2 (1.00g) and 2-[2-[(5-bromopentyl)oxylethyl] quinoline (0.97g). The product from FCC (eluting with System A (44:5:1) and (39:10:1)) was dissolved in ethyl acetate (60mg), washed with B% sodium bicarbonate solution (30mg), brine (30m%), dried and evaporated in vacuo. The residual gum (~1g) was dissolved in hot isopropanol (12m) and treated with fumaric acid (125mg). The hot solution was filtered and the crystals which deposited on cooling were collected by filtration. A further recrystallisation from isopropanol (20m) afforded the title compound (0.71q) m.p. 140-1439 (after being dried at 500/lmm Hg for 6h.), t.l.c. (System A 39:10:1) RF 0.52.
Analysis Found: C,58.9; H,5.9; N,7.65; €l1,14.2.
CpuHygC1,N;0,0-5C, 1,0, -0.05CHg0.0. 41,0 requires c,59.2; H,6.1; N,7.9% C1,13.4%.
Example 3 4-Amino-3 ,5-dichloro-g-[[[6=[2-(2-nethyl-4-thiazolyl)ethoxy hexyl] aminolmethyl]benzenemethanol
From 4-[2-[ (6-bromohexyl oxy lethyl]-2-methylthiazole (1.2q) and
Intermediate 2 (1.309), heating the reaction mixture for 1l.5hr. FCC eluting with System B (97:3:1) gave an oil which when triturated with hexane gave the title compound 8s a white solid (0.78g) m.p. 67-690.
Analysis Found: €,53.9; H,6.6; N,9.3; c1,15.7; S,7.2. . 35 C,oH,9C1,N;30,S requires c,53.8; H,6.6; N,9.4; C1,15.9; S,7.2% a - 29 - Co
Example 4 4-Amino-3,5-dichloro-a-[[[5-[3-(Lii-benzimidazol-2-y1l)propoxy pentyl] amino]methyl]l:znzenemethanol, (E)-butencdioate salt (2:1)
From Intermediate 2 (0.87g), and 2-[3-[ (5S-bromopentyl)oxy]
S propyl]-li-benzimidazole (0.85g), heating the reaction mixture for 3h. } FCC eluting with System B (95:5:1) gave a brown oil which was 4 dissolved in methanol (15m%) end treated with fumaric acid (0.08g).
B ; The solution was evaporated and triturated with diethyl ether to give 3 an orange solid. Treatment with hot isopropanol-ether (ca 1:4) followed by evaporation in vacuo gave a yellow foam, which was dried in vacuo at ca 40° for 10h to ive the title compound as a yellow solid (335mg) m.p. 55-600 (decomp), t.l.c. (System A 40:10:1) Rf 0.51.
Example 5 4-Amino-3,5-dichloro-u-[[[6-[[6-(2-pyrimidinyl)hexyl]oxyJhexyllamino]~ methyl]benzenemethanol
A mixture of Intermediate 2 (0.669), 2-16-[ (6-bromohexyl)oxy] hexyl]pyrimidine (0.66qg), DEA (0.64m2) and DMF (l4m2) was heated at 90% for 4h, cooled and evaporated in vacuo. The oily residue was purified by FCC with System B (94:5:1) to give a product (705mg), which was dissolved in methanol (7m2) and fumaric acid (85mg) added.
The solution was evaporated in vacuo and the residue triturated with dry ether causing crystallisation, then recrystallised from isopropanol (7m%). The hygroscopic crystals were rapidly collected by
Filtration and partitioned between ethyl acetate (75mg) and 8% sodium bicarbonate solution (25mf). The organic phase was dried end evaporated in vacuo to give a gum which was further purified by FCC eluting with System B (96:3:1 - 94:5:1) to give a gum. Trituration with hexane afforded the title compound as a colourless powder (320mg) m.p. 55-570.
Analysis Found: €,59.5; H,7.65 N,11.4; Cl1,14.8.
C,,H36C1,N, 0, requires C,59.6; H,7.5; N,11.6; C1,14.7%. 35 .
Example 6 4-Amino-3,5-dichloro-a-[[[6-[[6-(5-pyrimidinyl)hexylloxyJhexylJamino}- methyl ]benzenemethanol
Intermediate 2 (1.33g) and S5-[6-[(6-bromohexyl)oxylhexyl] ; 5 pyrimidine (1.32g) were dissolved in DMF (22m) containing DEA es (1.02ml) and heated at 100-1100 for 2h, cooled and cvaporated in a vacuo. The residue was purified by FCC. Elution with toluene and tl System B (97:2:1-94:5:1) followed by System B (89:10:1) gave the desired product (380mg) followed by mixed fractions. The mixed fractions were dissolved in methanol (ém%) and fumeric acid (80mg) added, then the solution evaporated in vacuo. The oily residue was slowly recrystallised from isopropanol (~10mf%) to afford the hygroscopic fumarate salt, which was taken up in methanol (~3mf%) and partitioned between 8% sodium bicarbonate solution (15m2) and ethyl acetate (50me). The organic phase was dried and evaporated in vacuo to give the product as a gum, which wes combined with the desired product obtained above. Trituration with hexane afforded the title ) compound as a pale yellow powder (620mg) m.p. 59-619, t.l.c. (System A oo 80:20:1) RF 0.47. : methyllbenzenemethanol
A solution of 4-amino-3,5-dichloro-a-[[[6-[2-(2-benzoxazolyl) ethoxy Jhexyl]l(phenylmethyl)aminolmethyllbenzenemethanol (1.099) in ethanol (25m) containing conc. hydrochloric acid - ethanol (1:9, 1.78m1) was added to a pre-hydrogenated suspension of 10% palladium on carbon (50% aqueous paste, 0.659) and hydrogenated at room temperature and pressure, then filtered through hyflo and evaporated in vacuo.
The residue was partitioned between 8% sodium bicarbonate (25m2) and ethyl acetate (50m) and the organic phase dried and evaporated in i vacuo to a semi solid. Purification by FCC over silica (Merck 60) eluting with System B (97:2:1 + 94:5:1) afforded the title compound as a gum, which crystallised after trituration with hexane to a white ; 35 solid (613mg) m.p. 85-879.
Analysis Found: C,59.1; H,6.2; N,8.85; C1,15.25; . €,3",4C1,N;04 requires C,59.2; H,6.3; N,9.0; Cl1,15.2%.
4-Amino-3,5-dichloro-a-[1-[[6-[2-(2-pyridinyl)ethoxylhexyllamino]- ethyl]lbenzenem:thanal, (E)-butenedioate salt (2:1) Co
A solution of 4-amino-3,5-dichloro-a~[1-[(phenylmethyl)[6-[2-(2- pyridinyl)ethoxyJhexyl]amino ethyl lbenzenemethanol (0.67g) in ethanol oo ~ (25m2) containing conc. hydrochloric acid-ethanol (1:9, 2.33m1) was 5 : . added to a prehydrogenated suspension of 10% palladium on charcoal “ "(50% aqueous paste, lg) in ethanol (20m) and hydrogenated at room temperature and pressure. The mixture was filtered through hyflo and evaporated in vacuo to an oil which was partitioned between 8% sodium bicarbonate (20mf) and ethyl acetate (60mf). The orgsnic phase was dried end evaporated in vacuo and the residue purifed by FCC eluting with System 8 (89:10:1) to give a gum. A solution of the gum in : methanol (15mt) was treated with fumaric acid (60mg) and evaporated in vacuo. The residue was triturated with dry ether to afford the title ' " compound as a colourless powder (381mg) m.p. 137-1390. . Analysis Found: C,56.8; H,6.9; N,B8.2; C1,13.9;
EE €,,H3,CL,N50,.0.5C,H,0, .0.5H,0 requires : C,56.8; H,6.75; N,8.3; C1,13.9%
Co Example 9 4-Amino-3,5-dichloro-a-[[[6-[1-methyl-3-(2-pyridinyl)propoxyJhexyll- amino]methyl]benzenemethanol, (E)-butenedicate salt (2:1) 4-Amino-3,5-dichloro-a-[[[6-[1-methyl-3-(2-pyridinyl) propoxy Jhexyl](phenylmethyl)aminoJmethylJbenzenemethanol (0.85g) was : hydrogenated according to the method of Example 8. FCC purification of the residue obtained from the ethyl acetate extract eluting with
System B (96:3:1 » 94:5:1) gave an oil (590mg). A solution of this 0il in ethanol (10m%) was treated with fumaric acid (75mg) and evaporated in vacuo. Trituration with hexane afforded the title compound as a colourless powder (585mg) m.p. 113-1150. . Analysis Found: €,57.8;4,6.6;N,7.9;C1,13.6.
CpqHy3CL,N50,.0.5C, 11,0, .0.4H,0 requires C,57.8;H,6.9;N,8.15C1,13.65%. ’ 35 4 ; : ! 3
Example 10 4-Amino-3,5-dichloro-a-[[[6-[[6-(pyrazinyl)hexyl]JoxyJhexyllamino]- methyl]benzenemethanol
A solution of 4-amino-a-(aminomethyl)-3,5-dichlorobenzenemethanol (1.2g), DEA (0.72m2) and (6-[(6-bromohexyl)oxylhexyllpyrazine (1.16qg) in DMF (10m) was heated at 100-1100 for 3h. The resulting dark
Fl a solution was evaporated in vacuo and the residue purified by FCC
Se : eluting with System B (96:2:2593:5:2) to give the title compound as
Sr pale yellow crystals (0.92g), m.p. 60-630.
Analysis Found: €,59.0; H,7.2; N,11.5; C1,15.15.
CauH36CL5N,0,.0.05H,0 requires €,59.5; H,7.5; N,11.6; C1,14.65%.
Example 11 4-Amino-3,5-dichloro-a-[[[6-[3-(2-thiazolyl)propoxy Jhexyllamino] methyl]benzenemethanol, (E) butenedioate salt (2:1)
A mixture of 4-amino-a-(aminomethyl)-3, S-dichlorobenzenemethanol (800mg), 2-[[ (6-bromohexy1)oxy Jpropyllthiazole (739mg) and DEA (390mg) in dry DMF (10mg) was heated at 80° for 2h under nitrogen. The : solvent was evaporated and the residue purified by FCC eluting with : 20 ,' System B (95:5:1) to give the base as a pale yellow oil (615mg). A : solution of the oil in methanol (5m%) was treated with a solution of fumaric acid (BOmg) in methanol (5mg). The solvent was, evaporated off cee
So and the residue triturated under ether (10mg) to give the title compound as a white powder (560mg), m.p. 113-40,
Analysis Found: C,51.9; H,5.9; N,8.0; 5,6.0; C1,13.2
C20H29C1,N30,5.0.5C,H,0, .0.5H,0 requires
C,51.5; H,6.3; N,B.2; §,6.2; C1,13.8%.
Example 12 4-Amino-3,5-dichloro-a-[[[6-[{6-(2-quinolinyl)hexylJoxylhexyllaminol- methyl]benzenemethanol
A solution of 2-[6-[(6-bromohexyl)oxyl-1-hexynyllquinoline (1.96g) in ethanol (100m&) was hydrogenated over pre-reduced 10% palladium oxide { on charcoal catalyst (750mg). The catalyst was removed by filtration . through hyflo end the filtrate eveporated to a brown oil (1.329). A solution of 4-amino-«-(aminomethyl)-3,5-dichlorobenzenemethanol ; (1.05g) and DEA (0.429) in DMF (30mR) was treated at 900 with a solution of the above brown oil (1.06g) in DMF (20m%). The solution was heated to 90-1009 under nitrogen for 3h, cooled and evaporated in vacuo to a gum. The residue was purified by FCC eluting with System B
(98:2:1) to give a pale yellow oil which was triturated with hexane to produce the title compound as a cream coloured powder (1.049). m.p. 62.3 - 64.70. : Analysis Found: £,65.45; H,7.7; N,7.8; Cl1,13.9. . NL U5 C,qH49C1,N30, requires C,65.40; H,7.4; N,8.0; C1,13.3%. nA : Example 13
GAA ©" 4-Amino-3,5-dichloro-a-[[[6-[[6-(2-pyridinyl)hexylJoxylhexyllamino]
Bre oo ~ methyllbenzenemethanol, (E)-butenedioate salt (2:1) hE 110 A solution of 4-amino-3,S5-dichloro-a-{(phenylmethyl)[6-[[6-(2- na co pyridinyl)-5-hexynylJoxylhexyllaminolmethyl Jbenzenemethanol (1.65g) in " - ethanol (30m) was hydrogenated over pre-reduced 10% palladium oxide . on charcoal catalyst (650mg) in ethanol (10m) containing hydrochloric . acid (conc. hydrochloric scid:ethanol 1:9, 5.27ml). The mixture was filtered through hyflo and evaporated in vacuo to give an oil which was dissolved in ethyl acetate (120mf) and washed with 8% sodium bicarbonate solution (100m2). The organic phase was dried and evaporated in vacuo to an oil and purified by FCC eluting with System
A (90:10:1 » B80:20:1) to give a pale brown oil (750mg). This was dissolved in methanol (20m2) and a solution of fumaric acid (91mg) in methanol (10m) was added. The solvent was evaporated to leave the title compound as a pale brown powder which was recrystallised from isopropanol and triturated under ether to give the title compound as a pale brown powder (490mg), m.p. 100-1020. :
Analysis Found: C,59.1;H,7.3;N,7.5;C1,12.7. *
C,5H37C1,N30,.0.5C,H,0,.0.5H,0 requires C,59.0;H,7.3;N,7.65;C1,12.9%.
Example 14 oo 4-Amino-3,5-dichloro-a-[[[6-[3-(2-quinolinyl)propoxyJhexyllamino] methyl]benzenemethanol, (E)-butenedioate salt (2:1) : A solution of 4-amino-a-{sminomethyl)-3,5-dichlorobenzenemethanol
I. (0.769), DEA (0.65m%) in DMF (12mf) was treated with 2-[3-[(6- . 3 bromohexyl)oxy Jpropyllquinoline (0.886g), heated at 115-1200 for 2h, : oo . cooled and evaporated in vacuo. The residue was purified by FCC : : 35 eluting with System B (96:2:2+94:5:1) to give the free base of the
Lo title compound (542mg), m.p. 44-49%. This was dissolved in methanol
(3 « voy (6m) and fumaric acid (64mg) added. The methanol was removed in
Yacuo and the residue recrystallised from isopropanol (15m) to give the title compound as colourless needles (517mg), m.p. 121-122.50,
Analysis Found: C,60.65H,6.2;N,7.5;C1,12.8.
C26133C15N;30,.0.5€,1,0,.0. 51,0 requires C,60.3;H,6.5;N,7.5;C1,12.7%
The following are examples of suitable formulations of compounds of the invention. The term 'active ingredient' is used herein to : represent a compound of the invention.
Tablets (Direct Compression) mg/tablet
Active ingredient 2.0 . Microcrystalline cellulose USP 196.5
Magnesium Stearate BP 1.5
Compression weight 200.0
The active ingredient is sieved through a suitable sievé, blended with the excipients and compressed using 7mm diameter punches.
Tablets of other strengths may be prepared by altering the ratio of active ingredient to microcrystalline cellulose or the compression weight and using punches to suit.
The tablets may be film coated with suitable film forming materials, such ag hydroxypropylmethylcellulose, using standard : techniques. Alternatively, the tablets may be sugar coated.
Metered Dose Pressurised Aerosol (Suspension Aerosol) mg/metered dose Per can
Active ingredient micronised 0.100 26.40mg
Oleic Acid BP 0.010 2.64mg
Trichlorofluoromethane BP 23.64 5.67¢g
Dichlorodifluoromethane Bp 61.25 14.709 . Co . - 35 - . Rd
<
The active ingredient is micronised in a fluid energy mill to a fine particle size range. The oleic acid is mixed with the trichlorofluoromethane at a temperature of 10-15% and the micronised : drug is mixed into the solution with a high shear mixer. The : 5 suspension is metered into aluminium aerosol cans and suitable
Le So metering valves delivering 85mg of suspension are crimped onto the oe cans and the dichlorodifluoromethane is pressure filled into the cans through the valves. '
Inhalation Cartridges ‘ mg/cartridge
Active ingredient micronised 0.200 ‘
Lactose BP to 25.0 i . 15 The active ingredient is micronised in a fluid energy mill to a Co i fine particle size range prior to blending with normal tebletting . grade lactose in a high energy mixer. The powder blend is filled into
No. 3 hard gelatin capsules on a suitable encapsulating machine. The contents in the cartridges are administered using a powder inhaler such as the Glaxo Rotahaler. t : { oo - 36 - Co
Claims (11)
1. A compound of the formula (I) 2 TN co HoN TR) prempenzockz et _ : / OH R? cl (1) or a physiologically acceptable salt or solvate thereof, wherein Q represents a chlorine atom; X represents a Ci_g2lkylene chain, and Y represents a Ci_gdlkylene chain with the proviso that the sum total or carbon atoms in the chains X and Y is not more than 10, and the chain CH,Y may be optionally substituted by one Cy-32tkN group; R represents a hydrogen atom or a C,_3alkyl group; R! and RZ each represent a hydrogen atom; and Het represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is {are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from Ci-q2tkyl, with the proviso that when Het represents a pyridyl group optionally substituted by one or two groups selected from Cq_3alkyl and Y represents a :
Ci.q21kylene chain, then, R represents a Cy-32Tkyl group and/or the chain -CH,Y- is substituted by one Cy.321ky1 Co group.
2. A compound according to claim 1 in which the sum total of carbon atoms in the chains X and Y is 4, 5, 6, 7, 8 or 9.
3. A compound according to claim 1 in which X represents -(CH,) 4 and y represents -(CHy),s -(CHy) 4- or -(CHy) =.
4. A compound according to claim 1 in which R represents a hydrogen atom.
5. A compound according to claim 1 in which Het represents So , , a group selected from pyrimidinyl, pyrazinyl, triazinyl, } } thiazolyl, quinolinyl, benzimadazolyl, benzothiazolyl, benzoxazolyl and pyridyl.
6. A compound according to claim 1 in which Het represents a pyrimidinyl or thiazolyl group.
7. 4-Amino-3,5-dichloro-a-[[[6-[3-(2-thiazoly1)propoxy]-hexy1]- amino Jmethyl]benzenemethanol; or a physiologically acceptable salt or solvate thereof.
8. A pharmaceutical composition for therapy or prophylaxis of a disease associated with reversible airways obstruction , which comprises an effective amount to alleviate said disease of one compound of formula (1) as defined in claim 1 or a ‘ physiologically acceptable salt or solvate thereof, together with a physiologically acceptable carrier or excipient.
9. A method of therapy or prophylaxis of a disease associated with reversible airways obstruction in a patient, which comprises administering to said patient an effective amount : to alleviate said disease of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.
10. A pharmaceutical composition according to claim 8 wherein said disease associated with reversible airways obstruction is asthma or chronic bronchitis.
11. A method of therapy or prophylaxis according to claim 9 wherein said disease associated with reversible airways obstruction is asthma or chronic bronchitis. LAWRENCE HENRY CHARLES LUNTS Inventor
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PH38346A PH26788A (en) | 1989-03-20 | 1989-03-20 | Chloroaniline derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PH38346A PH26788A (en) | 1989-03-20 | 1989-03-20 | Chloroaniline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26788A true PH26788A (en) | 1992-10-13 |
Family
ID=19935734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH38346A PH26788A (en) | 1989-03-20 | 1989-03-20 | Chloroaniline derivatives |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH26788A (en) |
-
1989
- 1989-03-20 PH PH38346A patent/PH26788A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4963564A (en) | Phenethanolamine derivatives | |
DE3448338C2 (en) | ||
AU596824B2 (en) | Dichloroaniline derivatives | |
US4937268A (en) | Chemical compounds | |
EP0181709B1 (en) | Dichloroaniline derivatives | |
DE3880628T2 (en) | PHENETHANOLAMINE DERIVATIVES. | |
JPS62187438A (en) | Ethanolamine compound | |
FR2567510A1 (en) | AMINOPHENOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
US4996218A (en) | Chloroaniline derivatives | |
US4959381A (en) | Pyridine compounds which have useful activity associated with reversible air ways obstruction | |
US4990664A (en) | Ethanolamine derivatives | |
PH26788A (en) | Chloroaniline derivatives | |
US5149698A (en) | Chloroaniline derivatives | |
GB2160863A (en) | Ethanolamine compounds | |
US4921867A (en) | Pyridine compounds useful for therapy or prophylaxis of a disease associated with airway obstruction | |
JPH0372448A (en) | Compound | |
GB2230523A (en) | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives | |
EP0219350A2 (en) | Ethanolamine compounds | |
PH26576A (en) | Phenenthanolamine derivatives | |
HU209285B (en) | Process for producing phenetanol-amine derivatives |